Some older adults should receive the new respiratory syncytial virus (RSV) vaccine, the U.S. Centers for Disease Control and Prevention (CDC) has concluded, while acknowledging that the risks of the shots may outweigh the benefits for some of the population. The CDC’s director on June 29 endorsed advice from the CDC’s vaccine advisory panel, known as…
FDA Panel Unanimously Endorses New RSV Antibody Drug for Infants
A panel of outside advisers to the U.S. Food and Drug Administration (FDA) voted in favor of approving a preventative antibody treatment for respiratory syncytial virus (RSV) for in newborns and infants. The unanimous vote by 21 members of the FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) on Thursday brings the monoclonal antibody, nirsevimab, closer to final approval by the FDA. All on…
After Decades of Set Back, First Ever RSV Approved: A Closer Look
The U.S. Food and Drug Administration (FDA) approved the first-ever respiratory syncytial virus (RSV) vaccine for adults aged 60 and over on Wednesday, almost 60 years after the first RSV vaccine trial was called off due to two vaccine-induced deaths. The vaccine is called Arexvy and was developed by GSK, formerly GlaxoSmithKline. According to the…
FDA Approves First-Ever RSV Vaccine for Older Adults
The U.S. Food and Drug Administration (FDA) approved the first-ever respiratory syncytial virus (RSV) vaccine for use in adults aged 60 and over on Wednesday. The approval of its drug Arexvy is a major victory for British pharmaceutical giant GlaxoSmithKline (GSK), which has been rushing to get its RSV vaccine out to the market before…
FDA Finds Rare Neurological Disorder Is ‘Potential Risk’ With Pfizer RSV Vaccine
The Food and Drug Administration (FDA) stated that two older adults who received Pfizer’s respiratory syncytial virus (RSV) vaccine during a clinical trial were subsequently diagnosed with a rare neurological disorder known as Guillain-Barré syndrome. Briefing documents (pdf) released on Feb. 24 ahead of this week’s meeting of the Vaccines and Related Biological Products Advisory…
FDA Finds Rare Neurological Disorder Is a ‘Potential Risk’ With Pfizer Vaccine
The Food and Drug Administration (FDA) said two people who received Pfizer’s respiratory syncytial virus (RSV) vaccine during a clinical trial were subsequently diagnosed with a rare neurological disorder known as Guillain-Barre syndrome. Briefing documents (pdf) released on Feb. 24 ahead of an upcoming meeting of the Vaccines and Related Biological Products Advisory Committee flagged…
FDA Finds Rare Neurological Disorder Is a ‘Potential Risk’ With Pfizer RSV Vaccine
The Food and Drug Administration (FDA) said two people who received Pfizer’s respiratory syncytial virus (RSV) vaccine during a clinical trial were subsequently diagnosed with a rare neurological disorder known as Guillain-Barre syndrome. Briefing documents (pdf) released on Feb. 24 ahead of an upcoming meeting of the Vaccines and Related Biological Products Advisory Committee flagged…
Respiratory Syncytial Virus–Prevention and Natural Treatments
RSV (Respiratory Syncytial Virus) is a common, highly contagious virus that causes infections of the lungs and respiratory tract spread by coughing or sneezing. Symptoms are usually mild and similar to the common cold for adults and older, healthy children. Babies under 12 months, the immune-compromised, and those with heart or lung disease are at…
Orange County Issues Emergency Declaration Due to Rising RSV Cases
November 1, 2022
admin
Emergency declarationLocal NewsOrange CountyRegional NewsRegional-Local Newsrespiratory syncytial virusRSVSouthern CaliforniaSouthern California OC NewsUS
0 Comment
SANTA ANA, Calif.—Citing a record number of pediatric hospitalizations and emergency room visits, Orange County was under a health emergency declaration Oct. 1, with the county health officer pointing to a sharp rise in cases of the respiratory infection RSV, combined with COVID-19 and flu. Cases of RSV, or respiratory syncytial virus, have been on…
Moderna Begins Late-Stage Study of RSV Vaccine Using mRNA Technology
February 23, 2022
admin
AMERICABusiness & EconomyBusinesses in COVID-19CCP VirusCompanieseconomyModernamRNArespiratory syncytial virusstudyUSUS NewsVaccineVaccines & Safety
0 Comment
Moderna Inc. said on Tuesday it had begun a late-stage study of its vaccine for Respiratory Syncytial Virus (RSV) based on the same technology used to develop its COVID-19 shots. The only approved product using messenger RNA (mRNA)is COVID-19 vaccine, but Moderna and rival Pfizer are rushing to tap the potential of the technology to…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`